New report explores hottest trends in Bipolar Disorder Drugs Market 2020-2024: Top Manufacturers (J& J, GSK, AbbVie, Pfizer, Novartis, Eli Lilly)

This report provides in-depth study on the current state of the Global Bipolar Disorder Drugs Market 2020-2024. Key players in the Global Bipolar Disorder Drugs Market have been identified through the secondary research and their market share has been determined through primary and secondary research.

Global Bipolar Disorder Drugs Market overview:

BIR Analyst covers the Major Players data, including: shipment, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the competitors better. This report also covers all the regions and countries of the world, which shows a regional development status, including market size.

Available Exclusive Sample Copy of this Report @ https://www.businessindustryreports.com/sample-request/263496 .

Treatment is usually life-long and often involves a combination of medications and psychotherapy. The disorder used to be called manic depression or manic-depressive illness. Several types of medications are used to treat bipolar disorder. These include mood stabilizers, antidepressants, and drugs that relieve anxiety. The primary treatments for bipolar disorder include medications and psychological counseling (psychotherapy) to control symptoms. The Global Bipolar Disorder Drugs Market is segmented on the basis of Product Type, Application, End Use Industry and Region.

On the Basis of Product Type segment, the Bipolar Disorder Drugs Market is sub segmented into Mood Stabilizers, Antipsychotic Drugs, Antidepressant Drugs and Other Drugs. Based on End Use Industry segment, the Bipolar Disorder Drugs Market is sub segmented into Hospital, Lab and Others.

Some of the Bipolar Disorder Drugs Market manufacturers involved in the market are AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly, Astellas Pharma, Allergan, Johnson & Johnson, GlaxoSmithKline, AbbVie, Pfizer, Novartis in World, effective mergers are some of the strategies adopted by the Bipolar Disorder Drugs Market manufacturers. New product launches and continuous technological innovations are the Bipolar Disorder Drugs Market strategies adopted by the major players.

Purchase this report online with 90 Pages, List of Tables & Figures and in-depth Table of Contents on "Bipolar Disorder Drugs Market Report 2020" @ https://www.businessindustryreports.com/buy-now/263496/single .

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study.

There are several manufacturers of Bipolar Disorder Drugss in Europe and North America. In North America, the demand for Bipolar Disorder Drugss is primarily driven by the Healthcare sector. Among the countries in Asia Pacific, the demand was substantially high in developing countries such as China and India. These countries have been witnessing rapid increase in its population along with expansion of their overall economies, which has led to increase in disposable income.

Grab Your Report at an Impressive Discount @ https://www.businessindustryreports.com/check-discount/263496 .

Top Industry News:

AbbVie Announces Positive Topline Results from Phase 3 Trial of VENCLEXTA (venetoclax) in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) on 23 March, 2020 -- AbbVie, a research-based global biopharmaceutical company, today announced the VIALE-A (M15-656) trial of VENCLEXTA (venetoclax) in combination with azacitidine versus azacitidine in combination with placebo met its dual primary endpoints of statistically significant improvement of overall survival (OS) and composite complete remission rate (CR + CRi) for patients with previously-untreated acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy. At the recommendation of an independent data monitoring committee (IDMC), and per the prespecified interim analysis plan, due to positive efficacy results at the first interim analysis for overall survival, the trial results will be reported early, and the data from the trial will be submitted to the U.S. FDA and global health authorities. Results will be presented at a future medical meeting or published in a peer-reviewed journal.

"For the past three decades, there have been few options for patients with AML who cannot receive or tolerate intensive chemotherapy or a bone marrow transplant," said Neil Gallagher, M.D., Ph.D., chief medical officer and vice president of development, AbbVie. "The positive results from VIALE-A support the clinical benefit of the venetoclax plus azacitidine combination in patients with AML who are ineligible for intensive chemotherapy and reflect our ongoing commitment to transform the standards of care for patients with hematologic malignancies."

AML is one of the most aggressive and difficult-to-treat blood cancers with a very low survival rate. Despite advances in available therapies and care, the 5-year survival rate for patients diagnosed with AML remains approximately 28%. AML typically worsens quickly, and due to age and comorbidities, not all patients are eligible to receive intensive chemotherapy. AML is the most common acute leukemia in the world. An estimated 160,000 people are currently living with the disease globally with an incidence rate of 103 new cases per 100,000 people.

The Phase 3 VIALE-A study evaluated the efficacy and safety of venetoclax in combination with azacitidine compared with placebo in combination with azacitidine. The study met its dual primary endpoints of OS and composite complete remission (CR + CRi). At the recommendation of an IDMC, and per the prespecified interim analysis plan, due to positive efficacy results at the first interim analysis for overall survival, the trial results will be reported early, and the data from the trial will be submitted to the U.S. FDA and global health authorities. The observed safety profile is generally consistent with the known safety profile of venetoclax combined with azacitidine as observed in previous Phase 1/2 studies and the known safety profiles of the two medications.

In November 2018, AbbVie received accelerated approval in the U.S. for VENCLEXTA in combination with azacitidine, decitabine, or low-dose cytarabine (LDAC) for the treatment of newly-diagnosed AML in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy based on the Phase 1/2 studies. Approval was also granted in Mexico, Israel, Puerto Rico, Peru, Brazil, Russia, Argentina, Guatemala, Uruguay, Lebanon, Bahrain, Kazakhstan, Panama, Saudi Arabia, Taiwan, Australia, Qatar, and United Arab Emirates.

Table of Contents:

1 Bipolar Disorder Drugs Product Definition
2 Global Bipolar Disorder Drugs Market Manufacturer Share and Market Overview
2.1 Global Manufacturer Bipolar Disorder Drugs Shipments
2.2 Global Manufacturer Bipolar Disorder Drugs Business Revenue
2.3 Global Bipolar Disorder Drugs Market Overview
3 Manufacturer Bipolar Disorder Drugs Business Introduction
3.1 AstraZeneca Bipolar Disorder Drugs Business Introduction
3.1.1 AstraZeneca Bipolar Disorder Drugs Shipments, Price, Revenue and Gross profit 2020-2024
3.1.2 AstraZeneca Bipolar Disorder Drugs Business Distribution by Region
3.1.3 AstraZeneca Interview Record
3.1.4 AstraZeneca Bipolar Disorder Drugs Business Profile
3.1.5 AstraZeneca Bipolar Disorder Drugs Product Specification
3.2 Bristol-Myers Squibb Company Bipolar Disorder Drugs Business Introduction
3.2.1 Bristol-Myers Squibb Company Bipolar Disorder Drugs Shipments, Price, Revenue and Gross profit 2020-2024
3.2.2 Bristol-Myers Squibb Company Bipolar Disorder Drugs Business Distribution by Region
3.2.3 Interview Record
3.2.4 Bristol-Myers Squibb Company Bipolar Disorder Drugs Business Overview
3.2.5 Bristol-Myers Squibb Company Bipolar Disorder Drugs Product Specification
3.3 Eli Lilly Bipolar Disorder Drugs Business Introduction
3.3.1 Eli Lilly Bipolar Disorder Drugs Shipments, Price, Revenue and Gross profit 2020-2024
3.3.2 Eli Lilly Bipolar Disorder Drugs Business Distribution by Region
3.3.3 Interview Record
3.3.4 Eli Lilly Bipolar Disorder Drugs Business Overview
3.3.5 Eli Lilly Bipolar Disorder Drugs Product Specification
3.4 Astellas Pharma Bipolar Disorder Drugs Business Introduction
3.5 Allergan Bipolar Disorder Drugs Business Introduction
3.6 Johnson & Johnson Bipolar Disorder Drugs Business Introduction
................... Request free sample to get a complete Table of Content

About us

BusinessindustryReports.com is digital database of comprehensive market reports for global industries. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined - we want to help our clients envisage their business environment so that they are able to make informed, strategic and therefore successful decisions for themselves.

Media Contact

Business Industry Reports

Pune - India

sales@businessindustryreports.com

+19376349940

This release was published on openPR.